The Li Ka Shing Foundation and Temasek Trust have pledged $8.8m (S$12m) to introduce innovative histotripsy cancer therapy trials in Singapore. This funding will equip the National Cancer Centre Singapore (NCCS) and the National University Cancer Institute, Singapore (NCIS) with the first Histotripsy Systems in Southeast Asia, targeting liver, kidney, and pancreatic cancers.
Histotripsy, developed by US-based HistoSonics, is a non-invasive ultrasound treatment that breaks down tumours at the cellular level without the need for surgery or radiation. This method offers a painless and scarless alternative to traditional cancer treatments. The clinical trial, set to begin later this year, aims to enrol 40 patients who meet specific criteria.
Professor Brian Goh Kim Poh, leading the trial at NCCS, highlighted the potential of histotripsy for patients unsuitable for invasive treatments due to factors like tumour location or underlying conditions. “Innovations such as histotripsy offer an alternative option with potential advantages as it is non-invasive,” he stated.
The initiative addresses the rising incidence of liver, kidney, and pancreatic cancers in Southeast Asia, driven by factors such as ageing populations and environmental exposure. In Singapore, liver cancer ranks as the third leading cause of cancer death among men.
The funding will be managed through a Donor-Advised Fund by TT Foundation Advisors, aiming to attract further philanthropic support for future cancer research. This strategic philanthropy seeks to ensure sustainable impact in advancing cancer treatment options in the region.
“`
